Two Industry Leaders Join Progenitor Cell Therapy Board
Complete the form below to unlock access to ALL audio articles.
Progenitor Cell Therapy, LLC (PCT) has announced that Mr. Robert Hamm and Professor K.K. Jain have both agreed to join its Board of Managers and that a majority vote of the Members has formally approved both appointments.
"The addition of Mr. Hamm and Professor Jain to the Board will add different and significant strengths to what is already an outstanding Board providing Progenitor Cell Therapy with significant guidance and insight," stated Dr. Andrew L. Pecora, Chairman of the Board.
"As a researcher and publisher, Professor Jain brings unrivalled knowledge of the global cell therapy sector."
"Mr. Hamm brings to the Board a wealth of manufacturing experience at a time when PCT is rapidly expanding its manufacturing facilities."
A brief biography of each new member follows.
Robert Hamm
Since 2003, Mr. Hamm has served at Biogen Idec where he is now Senior Vice President Strategic Neurology Business Unit.
Mr. Hamm joined Biogen in 1994 and has served in various management positions, including Senior Vice President, International, President of Biogen Europe, Vice President, Sales and Marketing, North America, and Vice President of Manufacturing and Engineering.
Prior to joining Biogen, his employment experience includes Syntex, Mobil Oil and the U.S. Air Force.
He received a B.A. in Psychology from St. Bonaventure University and an M.A. in Management Leadership from Central Michigan University.
Professor K. K. Jain
Professor K. K. Jain is a physician trained in neurology/neurosurgery. He worked for twenty-five years in various academic and private practice positions worldwide, mostly in Canada and the United States.
He has been involved in the biopharmaceutical industry since 1990, with a particular interest in cell/gene therapy, when he founded Jain PharmaBiotech.
Since 1997 Professor Jain has been an advocate for the development of personalized medicine and has promoted the integration of molecular diagnostics, biomarkers, proteomics, nanobiotechnology and RNAi to advance personalized medicine.
He was elected a fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of United Kingdom in 2000.
He is author of 370 publications, including 12 books and 46 special reports, covering a wide range of topics in biotechnology, healthcare and biopharmaceuticals, including the world's leading report in cell therapy.
